Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
What is the ticker symbol for Erasca, Inc.? What does ERAS stand for in stocks?
ERAS is the stock ticker symbol of Erasca, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Erasca, Inc. (ERAS)?
As of Wed Nov 20 2024, market cap of Erasca, Inc. is 746.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of ERAS stock?
You can check ERAS's fair value in chart for subscribers.
Is Erasca, Inc. a good stock to buy?
The fair value guage provides a quick view whether ERAS is over valued or under valued. Whether Erasca, Inc. is cheap or expensive depends on the assumptions which impact Erasca, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ERAS.